Ypsomed Holding AG
YPSN
Rangering i aksjer
#2948
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and... Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Aksjekurs
$469.39
Markedsverdi
$6.17B
Endring (1 dag)
1.63%
Endring (1 år)
18.98%
Land
CH
Handel Ypsomed Holding AG (YPSN)
Kategori
Healthcare
P/E-forhold for Ypsomed Holding AG (YPSN)
P/E-forhold per 2026 TTM: 0
Ifølge Ypsomed Holding AG sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Ypsomed Holding AG fra 2002 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2025 | 52.96 | -14.36% |
| 2024 | 61.85 | 22.83% |
| 2023 | 50.35 | -43.56% |
| 2022 | 89.21 | -74.08% |
| 2021 | 344.22 | 156.38% |
| 2020 | 134.26 | 397.39% |
| 2019 | 26.99 | -23.24% |
| 2018 | 35.17 | -32.11% |
| 2017 | 51.80 | 7.19% |
| 2016 | 48.33 | -18.25% |
| 2015 | 59.12 | -17.99% |
| 2014 | 72.08 | -82.56% |
| 2013 | 413.31 | 406.81% |
| 2012 | 81.55 | -40.99% |
| 2011 | 138.21 | 59.97% |
| 2010 | 86.40 | 183.61% |
| 2009 | 30.46 | -15.15% |
| 2008 | 35.90 | -90.80% |
| 2007 | 390.29 | 859.06% |
| 2006 | 40.70 | 23.88% |
| 2005 | 32.85 | 103.69% |
| 2004 | 16.13 | 3.77% |
| 2003 | 15.54 | -89.36% |
| 2002 | 146.00 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 26.50 | - |
IE
|
|
| 81.39 | - |
CN
|
|
| - | - |
CH
|
|
| 22.17 | - |
CN
|
|
| 19.80 | - |
KR
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.